This study evaluates the duration of intraocular pressure (IOP)-lowering effect and safety of as needed administrations of Bimatoprost sustained release (SR) in participants with open-angle glaucoma (OAG) or ocular hypertension (OHT) who are not adequately managed with topical IOP-lowering medication for reasons other than medication efficacy.
Study Eye: Cycles 1 - 3 administrations through the PRN treatment period. Fellow Eye: Standard of care or Bimatoprost SR.
CABA, Buenos Aires, Argentina
Pilar, Buenos Aires, Argentina
Ciudad de Buenos Aires, Buenos Aires F.D., Argentina
Rosario, Santa Fe Province, Argentina
Buenos Aires, Argentina
Ciudad Autonoma Buenos Aires, Argentina
Mendoza, Argentina